Pharvaris N.V.
deucrictibant
hereditary angioedema (HAE)
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on deucrictibant for hereditary angioedema (HAE) is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 11h ago
“Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.”